US20090326452A1 - Intradermal needle - Google Patents
Intradermal needle Download PDFInfo
- Publication number
- US20090326452A1 US20090326452A1 US12/554,280 US55428009A US2009326452A1 US 20090326452 A1 US20090326452 A1 US 20090326452A1 US 55428009 A US55428009 A US 55428009A US 2009326452 A1 US2009326452 A1 US 2009326452A1
- Authority
- US
- United States
- Prior art keywords
- limiter
- needle cannula
- assembly
- needle
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003491 skin Anatomy 0.000 claims abstract description 128
- 238000002347 injection Methods 0.000 claims abstract description 68
- 239000007924 injection Substances 0.000 claims abstract description 68
- 241001465754 Metazoa Species 0.000 claims abstract description 56
- 239000000126 substance Substances 0.000 claims abstract description 53
- 210000004207 dermis Anatomy 0.000 claims abstract description 28
- 230000035515 penetration Effects 0.000 claims abstract description 13
- 229960005486 vaccine Drugs 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 11
- 238000005452 bending Methods 0.000 claims description 7
- 229920001971 elastomer Polymers 0.000 claims description 4
- 239000000806 elastomer Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- -1 IgE suppressors Chemical compound 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 229940122853 Growth hormone antagonist Drugs 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010060162 alglucerase Proteins 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 229920006332 epoxy adhesive Polymers 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3245—Constructional features thereof, e.g. to improve manipulation or functioning
- A61M2005/3247—Means to impede repositioning of protection sleeve from needle covering to needle uncovering position
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/3278—Apparatus for destroying used needles or syringes
- A61M2005/3284—Deformaton of needle by deflection or bending
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0445—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/281—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
- A61M5/282—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule by compression of deformable ampoule or carpule wall
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3213—Caps placed axially onto the needle, e.g. equipped with finger protection guards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
- A61M5/5086—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile for indicating if defective, used, tampered with or unsterile
Definitions
- the present invention generally relates to a needle assembly attachable to a prefillable container for delivering substances such as drugs, vaccines and the like used in the prevention, diagnosis, alleviation, treatment, or cure of disease into the skin of an animal using an injection device having a needle cannula and a limiter for engaging the surface of the skin and limiting penetration of the tip of the needle cannula into the skin.
- the limiter limits penetration of the needle cannula from approximately 1.0 mm to approximately 2.0 mm, and most preferably around 1.5 mm ⁇ 0.2 mm to 0.3 mm, such that the substance is injected into the dermis layer of the animal.
- the orientation of the needle cannula is fixed so that the needle cannula is preferably generally perpendicular to the plane of the skin engaging surface of the limiter within about fifteen degrees or more preferably ninety degrees within about five degrees, and the skin engaging surface is generally flat.
- Intradermal injections are used for delivering a variety of substances. Many of these substances have proven to be more effectively absorbed into or react with the immune response system of the body when injected intradermally. Recently, clinical trials have shown hepatitis B vaccines administered intradermally are more immunogenic than if administered intramuscularly.
- substances have been injected intradermally for diagnostic testing, such as, for example using what is known in the art as the “Mantoux test” to determine the immunity status of the animal against tuberculosis and the immediate hypersensitivity status of Type I allergic diseases. It is desirable, in some instances, to provide a prefilled container filled with one of these substances and to mate the needle cannula to the container just prior to administering the injection.
- An intradermal injection is made by delivering the substance into the epidermis and upper layer of the dermis.
- Below the dermis layer is subcutaneous tissue (also sometimes referred to as the hypodermis layer) and muscle tissue, in that order.
- subcutaneous tissue also sometimes referred to as the hypodermis layer
- muscle tissue in that order.
- the skin thickness There is considerable variation in the skin thickness both between individuals and within the same individual at different sites of the body.
- the outer skin layer, epidermis has a thickness between 500-200 microns
- the dermis, the inner and thicker layer of the skin has a thickness between 1.5-3.5 mm.
- a needle cannula that penetrates the skin deeper than about 3.0 mm has a potential of passing through the dermis layer of the skin and making the injection into the subcutaneous region, which may result in an insufficient immune response, especially where the substance to be delivered intradermally has not been indicated for subcutaneous injection.
- the needle cannula may penetrate the skin at too shallow a depth to deliver the substance and result in what is commonly known in the art as “wet injection” because of reflux of the substance from the injection site.
- the standard procedure for making an intradermal injection is known to be difficult to perform, and therefore dependent upon experience and technique.
- This procedure is recommended to be performed by stretching the skin, orienting the needle bevel to face upwardly, and inserting a 26 Gauge short bevel needle cannula to deliver a volume of 0.5 ml or less of the substance into the skin of an animal with the needle cannula being inserted into the skin at an angle varying from around 10-15 degrees to form a blister or wheal in which the substance is deposited or otherwise contained.
- the technique utilized to perform the standard intradermal injection is difficult and requires the attention of a trained nurse or medical doctor. Inserting the needle to a depth greater than about 3.0 mm typically results in a failed intradermal injection because the substance being expelled through the cannula will be injected into the subcutaneous tissue of the animal.
- the most frequent cause of a failed intradermal injection is derived from inserting the needle into the skin at an angle greater than 15 degrees relative to the flattened skin surface.
- a further cause of error is derived from pinching rather than stretching the skin in the area of the injection, which is normally done when giving a subcutaneous rather than an intradermal injection. Pinching increases the likelihood of giving a subcutaneous injection.
- Procedural errors as described above result in delivering the contents of the injection into the subcutaneous layer, which can reduce the effectiveness of the injection, as well as possibly deliver the substance in a way not approved for delivery.
- Intradermal injections performed by using the standard procedure also are known to cause a significant amount of pain to the recipient of the injection because the needle cannula is inserted into the skin at an angle of about fifteen degrees.
- a needle assembly attachable to a prefillable container enabling a simplified method of performing an intradermal injection of substances which overcomes the problems and limitations associated with the use of conventional devices, especially reducing the probability of error and pain caused from the injection by making such injections less dependent upon experience and technique.
- pressure is applied to mask the pain derived from the intradermal injection by stimulating the muscle fibers to block the pain receptors. Still further, there has been a need to provide an needle assembly capable of addressing each of these shortcomings and yet be mated to the prefilled container just prior to administering the injection.
- the plane is generally perpendicular to the axis of the needle cannula within about five degrees.
- the hub portion and the limiter portion are formed as separate pieces, with the limiter portion defining an inner cavity receiving at least a portion of the hub and including an abutment engaging a corresponding structure on the hub portion thereby limiting the length of the needle cannula extending beyond the skin engaging surface.
- the hub portion includes a throat for receiving the prefillable container, with the needle cannula fixedly attached to the hub portion, preferably with an adhesive including an epoxy curable with ultra violet light.
- the limiter portion includes a plurality of snaps engaging the hub portion thereby fixedly attaching the hub portion to the limiter portion.
- the limiter portion and the hub portion are integrally formed as a single component, with the needle cannula fixedly attached to the hub portion of the single component behind the skin engaging surface of the limiter portion, with the hub portion including a throat for receiving the prefillable container and with the needle cannula fixedly attached to the hub portion with an adhesive.
- the skin engaging surface comprises a rigid polymer having an elastomeric central area with the needle cannula extending therethrough.
- the substance includes an influenza vaccine.
- the needle assembly is attachable to a prefillable container with a Luer fit.
- the assembly further includes a sleeve circumscribing the limiter and being slidable for shielding the forward tip subsequent to administering an intradermal injection, with the limiter including at least one ramp allowing the limiter to be moved toward the forward tip and preventing the limiter from being moved away from the forward tip upon shielding the forward tip.
- a tip cap is removably affixed to the skin engaging surface and has the forward tip received therein.
- the limiter includes a needle plunger slidably received thereby and is oriented generally perpendicular to the axis of the needle cannula within about fifteen degrees.
- the needle plunger is depressable thereby bending the needle cannula and retracting the needle cannula into the limiter for shielding the forward tip subsequent to administering an injection.
- the skin engaging surface includes an outer diameter of at least 5 mm.
- the preferred embodiment of the assembly further includes a forward cap being matable to a rearward cap wherein the caps enclose the needle assembly therebetween, with the forward cap and the rearward cap forming a sterile enclosure for storing the needle assembly.
- the hub portion and the limiter portion are formed as separate pieces, with the limiter portion defining an inner cavity receiving at least a portion of the hub and including an abutment engaging a corresponding structure on the hub portion thereby limiting the length of the needle cannula extending beyond the skin engaging surface.
- needle cannula is fixedly attached to the hub portion preferably with an adhesive including an epoxy curable with ultra violet light.
- the limiter portion includes a plurality of snaps engaging the hub portion thereby fixedly attaching the hub portion to the limiter portion.
- the limiter portion and the hub portion are integrally formed as a single component, with the needle cannula preferably fixedly attached to the hub portion of the single component behind the skin engaging surface of the limiter portion.
- the skin engaging surface comprises a rigid polymer having an elastomeric central area with the needle cannula extending therethrough, and needle assembly is attachable to a prefillable container with a Luer fit.
- a sleeve circumscribes the limiter and is slidable for shielding the forward tip subsequent to administering an intradermal injection, with the limiter including at least one ramp allowing the limiter to be moved toward the forward tip and preventing the limiter from being moved away from the forward tip upon shielding the forward tip.
- the assembly may also include a tip cap removably affixed to the skin engaging surface and having the forward tip received therein.
- the limiter may include a needle plunger slidably received thereby and oriented generally perpendicular to the axis of the needle cannula, with the needle plunger preferably depressable thereby bending the needle cannula and retracting the needle cannula into the limiter for shielding the forward tip subsequent to administering an injection.
- a forward cap is matable to a rearward cap wherein the caps enclose the needle assembly therebetween, with the forward cap and the rearward cap forming a sterile enclosure for storing the needle assembly.
- the intradermal needle assembly of the present invention attachable to a prefillable container having a reservoir adapted to contain a substance for use in intradermally injecting vaccines into the skin of an animal, includes a needle cannula affixed to a hub portion and being in fluid communication with the outlet port, the needle having a forward tip that is adapted to penetrate an the skin of an animal, and a limiter surrounding the needle cannula and having a generally flat skin engaging surface extending in a plane ranging between five and fifteen degrees from perpendicular to an axis of the needle cannula and being adapted to be placed against the skin of the animal to administer an intradermal injection of the substance, the needle forward tip extending away from the skin engaging surface from approximately 0.5 mm to approximately 3.0 mm such that the limiter limits penetration of the forward tip into the dermis layer of the skin of an animal so that the substance is injected into the dermis layer of the skin.
- the hub portion and the limiter portion are formed as separate pieces, with the limiter portion defining an inner cavity receiving at least a portion of the hub and including an abutment engaging a corresponding structure on the hub portion thereby limiting the length of the needle cannula extending beyond the skin engaging surface.
- the assembly for use with a prefillable container having a reservoir capable of storing a substance for injection into the skin of an animal, the assembly includes a hub portion being attachable to the prefillable container storing the substance, a needle cannula supported by the hub portion and having a forward tip extending away from the hub portion, a limiter portion surrounding the needle cannula and extending away from the hub portion toward the forward tip of the needle cannula, the limiter including a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of the needle cannula and adapted to be received against the skin of the animal to administer an intradermal injection of the substance, the needle forward tip extending beyond the skin engaging surface a distance approximately 0.5 mm to 3.0 mm wherein the limiter portion limits penetration of the needle into the dermis layer of skin of the animal so that the vaccine is injected into the dermis layer of the animal, and an enclosure means for concealing the needle cannul
- the enclosure means comprises the limiter being slideably disposed about the needle cannula and having at least a first position and a second position, the first position exposing the forward tip of the needle cannula and the second position concealing the forward tip of the needle cannula, with the limiter preferably defining at least one slot oriented generally parallel to the needle cannula and having a protuberance disposed on one side thereof.
- the assembly includes a hub supporting the needle cannula and the hub including at least one locking finger and at least one stop, the at least one locking finger being cantilevered away from the forward tip and the at least one stop being cantilevered toward the forward tip, with the at least one locking finger including a tab received by the slot disposed in the limiter.
- the tab is snappable over the protuberance for moving the limiter from the first position to the second position, with the protuberance is disposed between the tab and the at least one stop when the limiter is located in the first position.
- the limiter may include a catch engaging the at least one stop when the limiter is in the second position thereby preventing the limiter from being moved into the first position from the second position.
- the limiter comprises a non-elastomeric polymer, with the skin engaging surface including an elastomeric polymer being circumscribed by the non-elastomeric polymer.
- the elastomeric polymer may be pierced by the needle cannula when the limiter is mated to the hub portion.
- the forward end the needle cannula includes a beveled tip ranging in length between approximately 0.8 mm and 1.0 mm, and approximately 0.9 mm.
- the enclosure means comprises a needle plunger inserted through the limiter and being depressable for bending the needle cannula thereby retracting the needle cannula into the limiter, with the needle plunger oriented generally perpendicular to the needle cannula.
- a cap is attachable to the skin engaging surface for concealing the forward tip, with the cap comprising an elastomer and the forward tip insertable into the elastomer to thereby sealing the needle cannula and prevent the substance from leaking from the prefillable container through the cannula.
- the enclosure means comprises a tubular shield extendable from a retracted position to an extended position enclosing the needle cannula.
- the needle forward tip extends beyond the skin engaging surface about 1.0 to 2.0 mm, and preferably 1.5 mm ⁇ 0.2 to 0.3 mm.
- the substance intradermally delivered in accordance with the method of the present invention is selected from the group consisting of drugs, vaccines and the like used in the prevention, diagnosis, alleviation, treatment, or cure of disease, with the drugs including Alpha-1 anti-trypsin, Anti-Angiogenesis agents, Antisense, butorphanol, Calcitonin and analogs, Ceredase, COX-II inhibitors, dermatological agents, dihydroergotamine, Dopamine agonists and antagonists, Enkephalins and other opioid peptides, Epidermal growth factors, Erythropoietin and analogs, Follicle stimulating hormone, G-CSF, Glucagon, GM-CSF, granisetron, Growth hormone and analogs (including growth hormone releasing hormone), Growth hormone antagonists, Hirudin and Hirudin analogs such as hirulog, IgE suppressors, Insulin, insulinotropin and analogs, Insulin-like growth factors, Interferons, Interleukins, lipo
- Pylori salmonella, diabetes, cancer, herpes simplex, human papilloma and the like other substances including all of the major therapeutics such as agents for the common cold, Anti-addiction, anti-allergy, anti-emetics, anti-obesity, antiosteoporeteic, anti-infectives, analgesics, anesthetics, anorexics, antiarthritics, antiasthmatic agents, anticonvulsants, anti-depressants, antidiabetic agents, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness preparations, antinauseants, antineoplastics, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, anticholinergics, benzodiazepine antagonists, vasodilators, including general, coronary, peripheral and cerebral, bone stimulating agents, central nervous system stimulants, hormones, hypnotics, immunosuppressives, muscle relaxants,
- the present invention provides the desirable features set forth above that are not presently included together on the same needle assembly.
- the needle assembly allows an intradermal injection to be made at a generally perpendicular angle to the skin of the animal and also be attached to a prefilled container just prior to administering the intradermal injection. Further, the intradermal needle assembly of this invention may be used for self-administration of intradermal injections.
- FIG. 1A is a partially exploded perspective view of the needle assembly of the present invention
- FIG. 1A is perspective view of the assembled caps of the needle assembly
- FIG. 2 is a perspective view of a prefillable container received by the needle assembly
- FIG. 3 is a side sectional view of the needle assembly
- FIG. 4 is a side sectional view of an alternative embodiment of the needle assembly
- FIG. 5 is a side sectional view of a second alternative embodiment of the needle assembly
- FIG. 6A is a perspective view of an alternative skin engaging surface of the needle assembly
- FIG. 6B is a perspective view of a second alternative skin engaging surface of the needle assembly
- FIG. 7 is a side sectional view of a further alternative embodiment of the needle assembly showing a sleeve and a tip cap;
- FIG. 8 is a side sectional view of the further alternative embodiment of the needle assembly showing the sleeve concealing the needle cannula;
- FIG. 9 is a side sectional view of a further alternative embodiment of the needle assembly showing a needle plunger.
- FIG. 10 is a side sectional view of the further alternative embodiment of the needle cannula showing the needle plunger retracting the needle cannula into the limiter.
- an intradermal needle assembly is generally shown at 10 .
- the assembly includes a limiter portion 12 and a hub portion 14 disposed inside the limiter portion 12 .
- a forward cap 16 is disposed upon the end of the hub portion 14 , and a rearward cap 17 is removably affixed to the forward cap 16 , the purpose of which will be explained further below.
- the hub portion 14 includes a throat 18 adapted to receive a prefillable container 20 , as shown in FIG. 2 .
- the prefillable container 20 includes a reservoir 21 adapted to store substances intended for intradermal delivery into the skin of an animal.
- the substances comprise drugs or vaccines known to be absorbed into or react with the immune response system of the body significantly better in the dermis layer of the skin of the animal as opposed to in the subcutaneous or intramuscular region of the animal.
- hepatitis B vaccines it has been determined, are significantly more immunogenic when injected into the dermis layer of the skin of an animal.
- the prefillable container 20 may be a container that is filled at a pharmaceutical manufacturer with a liquid substance and sealed with a tip cap (not shown) for later use with the assembly 10 of the present invention.
- the prefillable container 20 may further be filled with a powder substance to which liquid is added just prior to administering the intradermal injection. Still further, the prefillable container may be filled with the entire substance just prior to administering the intradermal injection.
- the prefillable container 20 can be any of a variety of designs such as, for example, a hypodermic syringe, cartridge, pen, and any other delivery device to which the assembly 10 may be attached that is designed to expel substances for injection into an animal.
- the assembly 10 might include threads (not shown) for attachment to a pen.
- the prefillable container 20 represented in the figures is intended for demonstration purposes only and does not limit the scope of the subject needle assembly 10 .
- the limiter portion 12 defines a tubular chamber 22 wherein the hub portion 14 is received.
- a plurality of snaps 24 are disposed on a wall 23 of the tubular chamber 22 and clasp a flange 26 circumscribing a rearward end 28 of the hub portion 14 thereby securing the hub portion 14 inside the tubular chamber 22 .
- the tubular chamber 22 includes a ridge 30 that abuts a forward edge 32 of the hub portion 14 .
- the forward edge 32 defines the periphery of hub 14 .
- a sheath 34 is centrally disposed to the forward edge 32 upon the hub portion 14 .
- a needle cannula 36 is received by the sheath 34 and defines an axis of the forward edge 32 .
- the needle cannula 36 is fixedly attached to the sheath 34 of the hub portion 14 .
- an adhesive 38 fixedly attaches the needle cannula 36 to a sheath 34 .
- an epoxy adhesive that is curable with ultraviolet light is used to fixedly attach the needle cannula 36 to the sheath 34 .
- other methods of affixing the needle cannula 36 to the sheath 34 may be used such as an interference fit.
- the needle cannula 36 includes a rearward needle end 40 that extends through the sheath 34 into the throat 18 of the hub portion 14 .
- the rearward needle end 40 is in fluid communication with the prefillable container 20 thereby allowing the substance disposed within the prefillable container 20 to be expelled through the needle cannula 36 .
- the prefillable container 20 will be inserted into the throat 18 just prior to administering the intradermal injection.
- the rearward needle end 40 may be extended and pointed (not shown) to be able to pierce the sealed prefillable container making the fluid connection.
- the throat 18 includes a tapered bottom 21 adapted to retain the inserted prefillable container 20 through a Luer Slip connection as is well known in the art of syringe retention.
- a Luer Lok connection (not shown) may be utilized to retain the prefillable container 20 within the throat 18 .
- the needle cannula 36 includes a forward tip 42 that is adapted to administer an intradermal injection.
- the forward tip 42 includes a beveled edge 44 ranging in length from approximately 0.8 mm to 1.0 mm. More preferably, the beveled edge 44 includes a length of approximately 0.9 mm.
- a standard bevel tip length ranges from approximately 1.3 mm to 1.6 mm. The reduced length of the present beveled edge 44 reduces the potential of the needle cannula 36 passing through the dermis layer of the skin of the animal and resulting in the substance from the prefillable container 20 being injected into the subcutaneous region of the animal and conversely also reduces the potential for leakage.
- the limiter portion 12 surrounds the needle cannula 36 and extends away from the hub portion 14 toward the forward tip 42 of the needle cannula 36 .
- the limiter portion 12 includes an opening or aperture 48 which closely receives the needle cannula 36 and a generally flat skin engaging surface 46 extending in a plane 146 that is generally perpendicular to the axis of the needle cannula 36 within about fifteen degrees of perpendicular or more preferable within about five degrees.
- the skin engaging surface 46 is adapted to be received against the skin of the animal to administer an intradermal injection of the substance.
- the skin engaging surface 46 is represented as being generally flat and continuous and provides for a stable placement of the needle assembly 10 against the animal's skin. Referring to FIG.
- the skin engaging surface may include an annular groove 47 with a central surface 49 circumscribing the needle cannula.
- FIG. 6B shows a skin engaging surface 46 having a plurality of spokes 51 projecting outwardly from the central surface 49 in a plane generally parallel to that of the central surface 49 .
- the skin engaging surface 46 provides stability for the device during injection and preferably has a cross-section of at least 5 mm or between 5 to 20 mm.
- the forward tip 42 of the needle cannula 36 extends beyond the skin engaging surface 46 a distance of approximately 0.5 mm to 3.0 mm and preferably about 1.0 to 2.0 mm, and more preferably 1.5 mm ⁇ 0.2 to 0.3 mm.
- the length the needle cannula 36 extends beyond the skin engaging surface 46 is determined by the position of the ridge 30 relative to the skin engaging surface 46 . Therefore, the limiter portion 12 limits penetration of the needle cannula 36 into the dermis layer of the skin of the animal so that the substance is injected into the dermis layer of the animal.
- the needle cannula 36 When the hub portion 14 is inserted into the tubular chamber 22 of the limiter portion 12 during assembly, the needle cannula 36 is inserted through an aperture 48 disposed in the skin engaging surface 46 of the limiter portion 12 . Thus, only the length of the needle cannula 36 extending through the aperture 48 is available to be inserted into the skin of the animal.
- the forward cap 16 conceals the forward tip 42 of the needle cannula 36 .
- the rearward cap 17 mates to the forward cap 16 and is removably secured with an interference fit provided by a plurality of annular ribs 43 disposed upon a surface of the rearward cap and abutting the forward cap 16 .
- the forward cap 16 includes an annular protuberance 45 positioned opposite the annular ribs 43 providing a snapping action when the forward cap 16 and the rearward cap 17 are mated.
- the caps 16 , 17 provide a sanitary enclosure for the assembly 10 .
- a tamper indicator strip 47 is positioned over a seam formed between the caps 16 , 17 .
- the strip 47 is perforated along the seam. A ripped or torn perforation indicates that the assembly 10 has been open and that the needle cannula 36 may no longer be sanitary.
- the alternative limiter portion 112 includes an alternative skin engaging surface 146 having an elastomeric central area 148 functioning as a piercable septum surrounded by a nonelastomeric substrate comprising the remainder of the skin engaging surface 146 and the alternative limiter 112 .
- the elastomeric central area 148 includes a larger diameter than the aperture 48 of the preferred embodiment.
- the assembly process of mating the hub portion 14 with the alternate limiter 112 will be more easily performed because the needle cannula 36 will not have to be inserted through a narrow aperture 48 .
- the elastomeric central area 148 provides uniform pressure on the skin of the animal facilitating the formation of a wheal in the skin.
- a second alternative embodiment is generally shown in FIG. 5 at 210 .
- the limiter portion 212 and the hub portion 214 are integrally formed as a single piece.
- the needle cannula 36 is fixedly attached to the hub portion 214 of the single component 210 behind a skin engaging surface 246 of the limiter portion 212 .
- the needle cannula 36 is inserted through an aperture 248 disposed in the skin engaging surface 246 .
- the needle cannula 36 is fixedly attached to a sheath 234 disposed in the hub portion 214 behind the skin engaging surface 246 .
- the needle cannula 36 is affixed through similar means as has been disclosed for the preferred embodiment.
- the rearward end 28 of the needle cannula 36 is disposed in the throat 218 of the hub portion 214 and thereby establishes fluid communication with the prefillable container 20 in a similar fashion as has been disclosed for the preferred embodiment.
- a third alternate assembly 310 adapted to shield the needle cannula 36 subsequent to administering an intradermal injection is shown.
- a sleeve 312 generally defining a tube slidably circumscribes the limiter 314 .
- the sleeve 312 includes a skin engaging end 316 that is aligned in generally the same plane as the skin engaging surface 318 when the assembly 310 is prepared for administering the intradermal injection.
- a rearward end 320 of the sleeve 312 is tapered inwardly towards the axis of the needle cannula 36 .
- an elastomeric tip cap 323 is removably secured to the skin engaging surface 318 and receives the forward tip 42 of the needle cannula 36 .
- the sleeve 312 may be manually pulled in the direction of the forward tip 42 of the needle cannula 36 as shown in FIG. 8 .
- the limiter 314 includes a sleeve stop 324 , which engages a corresponding contour 326 disposed on an inside surface of the sleeve 312 thereby preventing the sleeve from being removed from the limiter 314 .
- At least one ramp 328 is disposed upon an outer surface of the limiter 314 over which the rearward end 320 of the sleeve 312 slides when the sleeve 312 is moved to cover the forward tip 42 of the needle cannula 36 .
- the ramp 328 locks the sleeve in the extended position and prevents the sleeve 312 from being retracted toward the prefillable container 20 re-exposing the forward tip 42 once the rearward end 320 of the sleeve 312 has been moved past the ramp 328 in the direction of the forward tip 42 .
- a needle plunger 412 is inserted through the limiter 414 at a generally perpendicular angle to the needle cannula 36 . Depressing a pad 416 disposed on a distal end of the needle plunger 412 drives the needle plunger 412 inwardly of the limiter 414 . As shown in FIG. 10 , needle plunger 412 , when depressed, contacts and bends the needle cannula 36 retracting the needle cannula 36 into the limiter 414 thereby shielding the forward tip 42 of the limiter 414 to prevent exposure thereto.
- the intradermal delivery device 10 of this invention includes a needle enclosure means, which encloses or conceals the needle cannula tip 42 following injection and which preferably cannot be retracted to prevent accidental needle contact or reuse.
- the assembly includes an extendable shield 312 , which locks in the extended position, preventing contact with the needle cannula 36 .
- the needle cannula 36 is bent or deformed beyond its elastic limit by needle plunger 412 to permanently enclose the forward tip 42 within the limiter 414 .
Abstract
An intradermal needle assembly that is attachable to a prefillable container intended for intradermally injecting substances into an animal includes a needle cannula supported by a hub portion. The hub portion is adapted to receive the prefillable container just prior to administering the intradermal injection. A limiter portion surrounds the needle cannula and extends away from the hub portion toward a forward tip of the needle cannula, and includes a skin engaging surface with the needle cannula having a fixed angle of orientation, preferably generally perpendicular, relative to the plane of the skin engaging surface. The skin engaging surface is received against the skin of an animal to administer an intradermal injection. The forward tip extends beyond the skin engaging surface a distance enabling penetration of the needle cannula into the dermis layer of the skin of the animal enabling injection of the substance into the dermis layer.
Description
- This application is a Divisional of U.S. patent application Ser. No. 11/010,175, filed on Dec. 10, 2004 which is a Continuation of U.S. patent application Ser. No. 09/834,438, filed on Apr. 13, 2001, which is a continuation-in-part of U.S. patent application Ser. No. 09/417,671, filed on Oct. 14, 1999, now U.S. Pat. No. 6,494,865.
- The present invention generally relates to a needle assembly attachable to a prefillable container for delivering substances such as drugs, vaccines and the like used in the prevention, diagnosis, alleviation, treatment, or cure of disease into the skin of an animal using an injection device having a needle cannula and a limiter for engaging the surface of the skin and limiting penetration of the tip of the needle cannula into the skin. Preferably, the limiter limits penetration of the needle cannula from approximately 1.0 mm to approximately 2.0 mm, and most preferably around 1.5 mm±0.2 mm to 0.3 mm, such that the substance is injected into the dermis layer of the animal. The orientation of the needle cannula is fixed so that the needle cannula is preferably generally perpendicular to the plane of the skin engaging surface of the limiter within about fifteen degrees or more preferably ninety degrees within about five degrees, and the skin engaging surface is generally flat.
- Intradermal injections are used for delivering a variety of substances. Many of these substances have proven to be more effectively absorbed into or react with the immune response system of the body when injected intradermally. Recently, clinical trials have shown hepatitis B vaccines administered intradermally are more immunogenic than if administered intramuscularly. In addition, substances have been injected intradermally for diagnostic testing, such as, for example using what is known in the art as the “Mantoux test” to determine the immunity status of the animal against tuberculosis and the immediate hypersensitivity status of Type I allergic diseases. It is desirable, in some instances, to provide a prefilled container filled with one of these substances and to mate the needle cannula to the container just prior to administering the injection.
- An intradermal injection is made by delivering the substance into the epidermis and upper layer of the dermis. Below the dermis layer is subcutaneous tissue (also sometimes referred to as the hypodermis layer) and muscle tissue, in that order. There is considerable variation in the skin thickness both between individuals and within the same individual at different sites of the body. Generally, the outer skin layer, epidermis, has a thickness between 500-200 microns, and the dermis, the inner and thicker layer of the skin, has a thickness between 1.5-3.5 mm. Therefore, a needle cannula that penetrates the skin deeper than about 3.0 mm has a potential of passing through the dermis layer of the skin and making the injection into the subcutaneous region, which may result in an insufficient immune response, especially where the substance to be delivered intradermally has not been indicated for subcutaneous injection. Also, the needle cannula may penetrate the skin at too shallow a depth to deliver the substance and result in what is commonly known in the art as “wet injection” because of reflux of the substance from the injection site.
- Due to the inherent limitations of the standard needle assembly, the standard procedure for making an intradermal injection is known to be difficult to perform, and therefore dependent upon experience and technique. This procedure is recommended to be performed by stretching the skin, orienting the needle bevel to face upwardly, and inserting a 26 Gauge short bevel needle cannula to deliver a volume of 0.5 ml or less of the substance into the skin of an animal with the needle cannula being inserted into the skin at an angle varying from around 10-15 degrees to form a blister or wheal in which the substance is deposited or otherwise contained. Accordingly, the technique utilized to perform the standard intradermal injection is difficult and requires the attention of a trained nurse or medical doctor. Inserting the needle to a depth greater than about 3.0 mm typically results in a failed intradermal injection because the substance being expelled through the cannula will be injected into the subcutaneous tissue of the animal.
- The most frequent cause of a failed intradermal injection is derived from inserting the needle into the skin at an angle greater than 15 degrees relative to the flattened skin surface. A further cause of error is derived from pinching rather than stretching the skin in the area of the injection, which is normally done when giving a subcutaneous rather than an intradermal injection. Pinching increases the likelihood of giving a subcutaneous injection. Procedural errors as described above result in delivering the contents of the injection into the subcutaneous layer, which can reduce the effectiveness of the injection, as well as possibly deliver the substance in a way not approved for delivery. Intradermal injections performed by using the standard procedure also are known to cause a significant amount of pain to the recipient of the injection because the needle cannula is inserted into the skin at an angle of about fifteen degrees. By inserting the needle cannula at this angle, about 5 mm to about 6 mm of the needle is actually inserted into the skin. This results in a significant disruption of the pain receptors dispersed throughout the upper layers of the skin. Also, self-administered intradermal injections are not possible using the present method.
- Accordingly, there has been a long felt need for a needle assembly attachable to a prefillable container enabling a simplified method of performing an intradermal injection of substances which overcomes the problems and limitations associated with the use of conventional devices, especially reducing the probability of error and pain caused from the injection by making such injections less dependent upon experience and technique. In addition, there has been a need to reliably limit the depth of penetration of the needle cannula into the skin of the animal to avoid entry into the subcutaneous layer of the skin as well as reliably fix the orientation of the needle cannula relative to the skin. Also, there has been a need to apply pressure to the skin of the animal to facilitate formation of the blister or wheal in the skin in which the substance is deposited or otherwise contained and avoid wet injections. Further, pressure is applied to mask the pain derived from the intradermal injection by stimulating the muscle fibers to block the pain receptors. Still further, there has been a need to provide an needle assembly capable of addressing each of these shortcomings and yet be mated to the prefilled container just prior to administering the injection.
- In contrast to the conventional needle assembly and delivery method discussed above, it has been found by the applicant that intradermally injecting substances into the skin can be performed in connection with the use of the present invention to effectively and reliably deliver such substances intradermally.
- The intradermal needle assembly of the present invention for use with a prefillable container having a reservoir capable of storing a substance for injection into the skin of an animal includes a hub portion being attachable to the prefillable container storing the substance, a needle cannula supported by the hub portion and having a forward tip extending away from the hub portion, and a limiter portion surrounding the needle cannula and extending away from the hub portion toward the forward tip of the needle cannula, the limiter including a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of the needle cannula and adapted to be received against the skin of the animal to administer an intradermal injection of the substance, the needle forward tip extending beyond the skin engaging surface a distance approximately 0.5 mm to 3.0 mm wherein the limiter portion limits penetration of the needle into the dermis layer of skin of the animal so that the vaccine is injected into the dermis layer of the animal.
- In the preferred embodiment of the assembly, the plane is generally perpendicular to the axis of the needle cannula within about five degrees. In addition, the hub portion and the limiter portion are formed as separate pieces, with the limiter portion defining an inner cavity receiving at least a portion of the hub and including an abutment engaging a corresponding structure on the hub portion thereby limiting the length of the needle cannula extending beyond the skin engaging surface. Also, the hub portion includes a throat for receiving the prefillable container, with the needle cannula fixedly attached to the hub portion, preferably with an adhesive including an epoxy curable with ultra violet light. The limiter portion includes a plurality of snaps engaging the hub portion thereby fixedly attaching the hub portion to the limiter portion.
- Also, in the preferred embodiment of the assembly, the limiter portion and the hub portion are integrally formed as a single component, with the needle cannula fixedly attached to the hub portion of the single component behind the skin engaging surface of the limiter portion, with the hub portion including a throat for receiving the prefillable container and with the needle cannula fixedly attached to the hub portion with an adhesive. In addition, the skin engaging surface comprises a rigid polymer having an elastomeric central area with the needle cannula extending therethrough. Further, the substance includes an influenza vaccine. Still further, the needle assembly is attachable to a prefillable container with a Luer fit.
- In addition, the assembly further includes a sleeve circumscribing the limiter and being slidable for shielding the forward tip subsequent to administering an intradermal injection, with the limiter including at least one ramp allowing the limiter to be moved toward the forward tip and preventing the limiter from being moved away from the forward tip upon shielding the forward tip. Also, a tip cap is removably affixed to the skin engaging surface and has the forward tip received therein. The limiter includes a needle plunger slidably received thereby and is oriented generally perpendicular to the axis of the needle cannula within about fifteen degrees. The needle plunger is depressable thereby bending the needle cannula and retracting the needle cannula into the limiter for shielding the forward tip subsequent to administering an injection. Further, the skin engaging surface includes an outer diameter of at least 5 mm. The preferred embodiment of the assembly further includes a forward cap being matable to a rearward cap wherein the caps enclose the needle assembly therebetween, with the forward cap and the rearward cap forming a sterile enclosure for storing the needle assembly.
- Alternatively, the intradermal needle assembly of the present invention for use with a prefillable container having a reservoir capable of storing a substance for injection into the skin of an animal includes a hub portion having a throat for receiving the prefillable container, a needle cannula being supported by the hub portion and having a forward tip extending away from the hub portion, and a limiter portion surrounding the hub portion and the needle cannula and extending away from the hub portion toward the forward tip of the needle, the limiter portion including a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of the needle cannula and being adapted to be received against the skin of an animal to receive an intradermal injection of a vaccine, and the forward tip extending beyond the skin engaging surface from approximately 0.5 mm to approximately 3.0 mm wherein the limiter portion limits penetration of the needle cannula into the dermis layer of the skin of the animal thereby injecting the substance into the dermis layer of the animal.
- In the preferred embodiment, the hub portion and the limiter portion are formed as separate pieces, with the limiter portion defining an inner cavity receiving at least a portion of the hub and including an abutment engaging a corresponding structure on the hub portion thereby limiting the length of the needle cannula extending beyond the skin engaging surface. Also, needle cannula is fixedly attached to the hub portion preferably with an adhesive including an epoxy curable with ultra violet light.
- Also, the limiter portion includes a plurality of snaps engaging the hub portion thereby fixedly attaching the hub portion to the limiter portion. In addition, the limiter portion and the hub portion are integrally formed as a single component, with the needle cannula preferably fixedly attached to the hub portion of the single component behind the skin engaging surface of the limiter portion.
- In addition, in the preferred embodiment, the skin engaging surface comprises a rigid polymer having an elastomeric central area with the needle cannula extending therethrough, and needle assembly is attachable to a prefillable container with a Luer fit. Also, a sleeve circumscribes the limiter and is slidable for shielding the forward tip subsequent to administering an intradermal injection, with the limiter including at least one ramp allowing the limiter to be moved toward the forward tip and preventing the limiter from being moved away from the forward tip upon shielding the forward tip. The assembly may also include a tip cap removably affixed to the skin engaging surface and having the forward tip received therein. Further, the limiter may include a needle plunger slidably received thereby and oriented generally perpendicular to the axis of the needle cannula, with the needle plunger preferably depressable thereby bending the needle cannula and retracting the needle cannula into the limiter for shielding the forward tip subsequent to administering an injection. In addition, a forward cap is matable to a rearward cap wherein the caps enclose the needle assembly therebetween, with the forward cap and the rearward cap forming a sterile enclosure for storing the needle assembly.
- Alternatively, the intradermal needle assembly of the present invention attachable to a prefillable container having a reservoir adapted to contain a substance for use in intradermally injecting vaccines into the skin of an animal, includes a needle cannula affixed to a hub portion and being in fluid communication with the outlet port, the needle having a forward tip that is adapted to penetrate an the skin of an animal, and a limiter surrounding the needle cannula and having a generally flat skin engaging surface extending in a plane ranging between five and fifteen degrees from perpendicular to an axis of the needle cannula and being adapted to be placed against the skin of the animal to administer an intradermal injection of the substance, the needle forward tip extending away from the skin engaging surface from approximately 0.5 mm to approximately 3.0 mm such that the limiter limits penetration of the forward tip into the dermis layer of the skin of an animal so that the substance is injected into the dermis layer of the skin.
- In the preferred embodiment of the assembly, the hub portion and the limiter portion are formed as separate pieces, with the limiter portion defining an inner cavity receiving at least a portion of the hub and including an abutment engaging a corresponding structure on the hub portion thereby limiting the length of the needle cannula extending beyond the skin engaging surface.
- In yet another embodiment of the intradermal needle assembly of the present invention for use with a prefillable container having a reservoir capable of storing a substance for injection into the skin of an animal, the assembly includes a hub portion being attachable to the prefillable container storing the substance, a needle cannula supported by the hub portion and having a forward tip extending away from the hub portion, a limiter portion surrounding the needle cannula and extending away from the hub portion toward the forward tip of the needle cannula, the limiter including a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of the needle cannula and adapted to be received against the skin of the animal to administer an intradermal injection of the substance, the needle forward tip extending beyond the skin engaging surface a distance approximately 0.5 mm to 3.0 mm wherein the limiter portion limits penetration of the needle into the dermis layer of skin of the animal so that the vaccine is injected into the dermis layer of the animal, and an enclosure means for concealing the needle cannula following injection.
- In the preferred embodiment, the enclosure means comprises the limiter being slideably disposed about the needle cannula and having at least a first position and a second position, the first position exposing the forward tip of the needle cannula and the second position concealing the forward tip of the needle cannula, with the limiter preferably defining at least one slot oriented generally parallel to the needle cannula and having a protuberance disposed on one side thereof. Also, the assembly includes a hub supporting the needle cannula and the hub including at least one locking finger and at least one stop, the at least one locking finger being cantilevered away from the forward tip and the at least one stop being cantilevered toward the forward tip, with the at least one locking finger including a tab received by the slot disposed in the limiter. The tab is snappable over the protuberance for moving the limiter from the first position to the second position, with the protuberance is disposed between the tab and the at least one stop when the limiter is located in the first position. The limiter may include a catch engaging the at least one stop when the limiter is in the second position thereby preventing the limiter from being moved into the first position from the second position.
- In the preferred embodiment, the limiter comprises a non-elastomeric polymer, with the skin engaging surface including an elastomeric polymer being circumscribed by the non-elastomeric polymer. The elastomeric polymer may be pierced by the needle cannula when the limiter is mated to the hub portion. Also, the forward end the needle cannula includes a beveled tip ranging in length between approximately 0.8 mm and 1.0 mm, and approximately 0.9 mm. In addition, the enclosure means comprises a needle plunger inserted through the limiter and being depressable for bending the needle cannula thereby retracting the needle cannula into the limiter, with the needle plunger oriented generally perpendicular to the needle cannula. Further, a cap is attachable to the skin engaging surface for concealing the forward tip, with the cap comprising an elastomer and the forward tip insertable into the elastomer to thereby sealing the needle cannula and prevent the substance from leaking from the prefillable container through the cannula.
- Also, the enclosure means comprises a tubular shield extendable from a retracted position to an extended position enclosing the needle cannula. In addition, the needle forward tip extends beyond the skin engaging surface about 1.0 to 2.0 mm, and preferably 1.5 mm±0.2 to 0.3 mm.
- Also, the substance intradermally delivered in accordance with the method of the present invention is selected from the group consisting of drugs, vaccines and the like used in the prevention, diagnosis, alleviation, treatment, or cure of disease, with the drugs including Alpha-1 anti-trypsin, Anti-Angiogenesis agents, Antisense, butorphanol, Calcitonin and analogs, Ceredase, COX-II inhibitors, dermatological agents, dihydroergotamine, Dopamine agonists and antagonists, Enkephalins and other opioid peptides, Epidermal growth factors, Erythropoietin and analogs, Follicle stimulating hormone, G-CSF, Glucagon, GM-CSF, granisetron, Growth hormone and analogs (including growth hormone releasing hormone), Growth hormone antagonists, Hirudin and Hirudin analogs such as hirulog, IgE suppressors, Insulin, insulinotropin and analogs, Insulin-like growth factors, Interferons, Interleukins, Leutenizing hormone, Leutenizing hormone releasing hormone and analogs, Low molecular weight heparin, M-CSF, metoclopramide, Midazolam, Monoclonal antibodies, Narcotic analgesics, nicotine, Non-steroid anti-inflammatory agents, Oligosaccharides, ondansetron, Parathyroid hormone and analogs, Parathyroid hormone antagonists, Prostaglandin antagonists, Prostaglandins, Recombinant soluble receptors, scopolamine, Serotonin agonists and antagonists, Sildenafil, Terbutaline, Thrombolytics, Tissue plasminogen activators, TNF-, and TNF-antagonist, the vaccines, with or without carriers/adjuvants, including prophylactics and therapeutic antigens (including but not limited to subunit protein, peptide and polysaccharide, polysaccharide conjugates, toxoids, genetic based vaccines, live attenuated, reassortant, inactivated, whole cells, viral and bacterial vectors) in connection with, addiction, arthritis, cholera, cocaine addiction, diphtheria, tetanus, HIB, Lyme disease, meningococcus, measles, mumps, rubella, varicella, yellow fever, Respiratory syncytial virus, tick borne japanese encephalitis, pneumococcus, streptococcus, typhoid, influenza, hepatitis, including hepatitis A, B, C and E, otitis media, rabies, polio, HIV, parainfluenza, rotavirus, Epstein Barr Virus, CMV, chlamydia, non-typeable haemophilus, moraxella catarrhalis, human papilloma virus, tuberculosis including BCG, gonorrhoea, asthma, atheroschlerosis malaria, E-coli, Alzheimers, H. Pylori, salmonella, diabetes, cancer, herpes simplex, human papilloma and the like other substances including all of the major therapeutics such as agents for the common cold, Anti-addiction, anti-allergy, anti-emetics, anti-obesity, antiosteoporeteic, anti-infectives, analgesics, anesthetics, anorexics, antiarthritics, antiasthmatic agents, anticonvulsants, anti-depressants, antidiabetic agents, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness preparations, antinauseants, antineoplastics, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, anticholinergics, benzodiazepine antagonists, vasodilators, including general, coronary, peripheral and cerebral, bone stimulating agents, central nervous system stimulants, hormones, hypnotics, immunosuppressives, muscle relaxants, parasympatholytics, parasympathomimetrics, prostaglandins, proteins, peptides, polypeptides and other macromolecules, psychostimulants, sedatives, sexual hypofunction and tranquilizers and major diagnostics such as tuberculin and other hypersensitivity agents.
- The present invention provides the desirable features set forth above that are not presently included together on the same needle assembly. The needle assembly allows an intradermal injection to be made at a generally perpendicular angle to the skin of the animal and also be attached to a prefilled container just prior to administering the intradermal injection. Further, the intradermal needle assembly of this invention may be used for self-administration of intradermal injections.
- Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:
-
FIG. 1A is a partially exploded perspective view of the needle assembly of the present invention; -
FIG. 1A is perspective view of the assembled caps of the needle assembly; -
FIG. 2 is a perspective view of a prefillable container received by the needle assembly; -
FIG. 3 is a side sectional view of the needle assembly; -
FIG. 4 is a side sectional view of an alternative embodiment of the needle assembly; -
FIG. 5 is a side sectional view of a second alternative embodiment of the needle assembly; -
FIG. 6A is a perspective view of an alternative skin engaging surface of the needle assembly; -
FIG. 6B is a perspective view of a second alternative skin engaging surface of the needle assembly; -
FIG. 7 is a side sectional view of a further alternative embodiment of the needle assembly showing a sleeve and a tip cap; -
FIG. 8 is a side sectional view of the further alternative embodiment of the needle assembly showing the sleeve concealing the needle cannula; -
FIG. 9 is a side sectional view of a further alternative embodiment of the needle assembly showing a needle plunger; and -
FIG. 10 is a side sectional view of the further alternative embodiment of the needle cannula showing the needle plunger retracting the needle cannula into the limiter. - Referring to
FIGS. 1A and 1B , an intradermal needle assembly is generally shown at 10. The assembly includes alimiter portion 12 and ahub portion 14 disposed inside thelimiter portion 12. Aforward cap 16 is disposed upon the end of thehub portion 14, and arearward cap 17 is removably affixed to theforward cap 16, the purpose of which will be explained further below. Thehub portion 14 includes athroat 18 adapted to receive aprefillable container 20, as shown inFIG. 2 . - The
prefillable container 20 includes areservoir 21 adapted to store substances intended for intradermal delivery into the skin of an animal. The substances comprise drugs or vaccines known to be absorbed into or react with the immune response system of the body significantly better in the dermis layer of the skin of the animal as opposed to in the subcutaneous or intramuscular region of the animal. Specifically, hepatitis B vaccines, it has been determined, are significantly more immunogenic when injected into the dermis layer of the skin of an animal. Theprefillable container 20 may be a container that is filled at a pharmaceutical manufacturer with a liquid substance and sealed with a tip cap (not shown) for later use with theassembly 10 of the present invention. Theprefillable container 20 may further be filled with a powder substance to which liquid is added just prior to administering the intradermal injection. Still further, the prefillable container may be filled with the entire substance just prior to administering the intradermal injection. - The
prefillable container 20 can be any of a variety of designs such as, for example, a hypodermic syringe, cartridge, pen, and any other delivery device to which theassembly 10 may be attached that is designed to expel substances for injection into an animal. For example, theassembly 10 might include threads (not shown) for attachment to a pen. Theprefillable container 20 represented in the figures is intended for demonstration purposes only and does not limit the scope of thesubject needle assembly 10. - Referring to
FIG. 3 , thelimiter portion 12 defines a tubular chamber 22 wherein thehub portion 14 is received. A plurality ofsnaps 24 are disposed on awall 23 of the tubular chamber 22 and clasp aflange 26 circumscribing arearward end 28 of thehub portion 14 thereby securing thehub portion 14 inside the tubular chamber 22. The tubular chamber 22 includes a ridge 30 that abuts a forward edge 32 of thehub portion 14. The forward edge 32 defines the periphery ofhub 14. Asheath 34 is centrally disposed to the forward edge 32 upon thehub portion 14. Aneedle cannula 36 is received by thesheath 34 and defines an axis of the forward edge 32. Theneedle cannula 36 is fixedly attached to thesheath 34 of thehub portion 14. Preferably, an adhesive 38 fixedly attaches theneedle cannula 36 to asheath 34. More preferably, an epoxy adhesive that is curable with ultraviolet light is used to fixedly attach theneedle cannula 36 to thesheath 34. However, other methods of affixing theneedle cannula 36 to thesheath 34 may be used such as an interference fit. - The
needle cannula 36 includes arearward needle end 40 that extends through thesheath 34 into thethroat 18 of thehub portion 14. When theprefillable container 20 is inserted into thethroat 18 therearward needle end 40 is in fluid communication with theprefillable container 20 thereby allowing the substance disposed within theprefillable container 20 to be expelled through theneedle cannula 36. Preferably, theprefillable container 20 will be inserted into thethroat 18 just prior to administering the intradermal injection. Therearward needle end 40 may be extended and pointed (not shown) to be able to pierce the sealed prefillable container making the fluid connection. Thethroat 18 includes a tapered bottom 21 adapted to retain the insertedprefillable container 20 through a Luer Slip connection as is well known in the art of syringe retention. Alternatively, a Luer Lok connection (not shown) may be utilized to retain theprefillable container 20 within thethroat 18. - The
needle cannula 36 includes aforward tip 42 that is adapted to administer an intradermal injection. Preferably, theforward tip 42 includes abeveled edge 44 ranging in length from approximately 0.8 mm to 1.0 mm. More preferably, thebeveled edge 44 includes a length of approximately 0.9 mm. A standard bevel tip length ranges from approximately 1.3 mm to 1.6 mm. The reduced length of the presentbeveled edge 44 reduces the potential of theneedle cannula 36 passing through the dermis layer of the skin of the animal and resulting in the substance from theprefillable container 20 being injected into the subcutaneous region of the animal and conversely also reduces the potential for leakage. - The
limiter portion 12 surrounds theneedle cannula 36 and extends away from thehub portion 14 toward theforward tip 42 of theneedle cannula 36. Thelimiter portion 12 includes an opening oraperture 48 which closely receives theneedle cannula 36 and a generally flatskin engaging surface 46 extending in aplane 146 that is generally perpendicular to the axis of theneedle cannula 36 within about fifteen degrees of perpendicular or more preferable within about five degrees. Theskin engaging surface 46 is adapted to be received against the skin of the animal to administer an intradermal injection of the substance. Theskin engaging surface 46 is represented as being generally flat and continuous and provides for a stable placement of theneedle assembly 10 against the animal's skin. Referring toFIG. 6A , the skin engaging surface may include anannular groove 47 with acentral surface 49 circumscribing the needle cannula.FIG. 6B shows askin engaging surface 46 having a plurality ofspokes 51 projecting outwardly from thecentral surface 49 in a plane generally parallel to that of thecentral surface 49. Theskin engaging surface 46 provides stability for the device during injection and preferably has a cross-section of at least 5 mm or between 5 to 20 mm. - The
forward tip 42 of theneedle cannula 36 extends beyond the skin engaging surface 46 a distance of approximately 0.5 mm to 3.0 mm and preferably about 1.0 to 2.0 mm, and more preferably 1.5 mm±0.2 to 0.3 mm. The length theneedle cannula 36 extends beyond theskin engaging surface 46 is determined by the position of the ridge 30 relative to theskin engaging surface 46. Therefore, thelimiter portion 12 limits penetration of theneedle cannula 36 into the dermis layer of the skin of the animal so that the substance is injected into the dermis layer of the animal. When thehub portion 14 is inserted into the tubular chamber 22 of thelimiter portion 12 during assembly, theneedle cannula 36 is inserted through anaperture 48 disposed in theskin engaging surface 46 of thelimiter portion 12. Thus, only the length of theneedle cannula 36 extending through theaperture 48 is available to be inserted into the skin of the animal. - Referring to
FIGS. 1A and 1B , theforward cap 16 conceals theforward tip 42 of theneedle cannula 36. Therearward cap 17 mates to theforward cap 16 and is removably secured with an interference fit provided by a plurality ofannular ribs 43 disposed upon a surface of the rearward cap and abutting theforward cap 16. Theforward cap 16 includes anannular protuberance 45 positioned opposite theannular ribs 43 providing a snapping action when theforward cap 16 and therearward cap 17 are mated. Thecaps assembly 10. To ensure theassembly 10 has not been accessed prior to administering the injection, atamper indicator strip 47 is positioned over a seam formed between thecaps strip 47 is perforated along the seam. A ripped or torn perforation indicates that theassembly 10 has been open and that theneedle cannula 36 may no longer be sanitary. - An alternative embodiment of the
limiter portion 112 is shown inFIG. 4 . Thealternative limiter portion 112 includes an alternativeskin engaging surface 146 having an elastomericcentral area 148 functioning as a piercable septum surrounded by a nonelastomeric substrate comprising the remainder of theskin engaging surface 146 and thealternative limiter 112. When thehub portion 14 is inserted into a throat of thealternate limiter 112 theforward tip 42 of theneedle cannula 36 pierces the elastomericcentral area 148 of theskin engaging surface 146. The elastomericcentral area 148 includes a larger diameter than theaperture 48 of the preferred embodiment. Therefore, it should be understood that the assembly process of mating thehub portion 14 with thealternate limiter 112 will be more easily performed because theneedle cannula 36 will not have to be inserted through anarrow aperture 48. Further, while administering the intradermal injection, the elastomericcentral area 148 provides uniform pressure on the skin of the animal facilitating the formation of a wheal in the skin. - A second alternative embodiment is generally shown in
FIG. 5 at 210. In this embodiment, thelimiter portion 212 and thehub portion 214 are integrally formed as a single piece. Theneedle cannula 36 is fixedly attached to thehub portion 214 of thesingle component 210 behind a skin engaging surface 246 of thelimiter portion 212. Preferably, theneedle cannula 36 is inserted through anaperture 248 disposed in the skin engaging surface 246. Theneedle cannula 36 is fixedly attached to asheath 234 disposed in thehub portion 214 behind the skin engaging surface 246. Theneedle cannula 36 is affixed through similar means as has been disclosed for the preferred embodiment. Additionally, therearward end 28 of theneedle cannula 36 is disposed in the throat 218 of thehub portion 214 and thereby establishes fluid communication with theprefillable container 20 in a similar fashion as has been disclosed for the preferred embodiment. - Referring to
FIG. 7 , a thirdalternate assembly 310 adapted to shield theneedle cannula 36 subsequent to administering an intradermal injection is shown. Asleeve 312 generally defining a tube slidably circumscribes thelimiter 314. Thesleeve 312 includes askin engaging end 316 that is aligned in generally the same plane as theskin engaging surface 318 when theassembly 310 is prepared for administering the intradermal injection. Arearward end 320 of thesleeve 312 is tapered inwardly towards the axis of theneedle cannula 36. Therearward end 320 abuts arear flange 322 of thelimiter 314, which prevents thesleeve 312 from being removed from thelimiter 314 in the direction of theprefillable container 20. In this embodiment, anelastomeric tip cap 323 is removably secured to theskin engaging surface 318 and receives theforward tip 42 of theneedle cannula 36. - Subsequent to administering the intradermal injection, the
sleeve 312 may be manually pulled in the direction of theforward tip 42 of theneedle cannula 36 as shown inFIG. 8 . Thelimiter 314 includes asleeve stop 324, which engages acorresponding contour 326 disposed on an inside surface of thesleeve 312 thereby preventing the sleeve from being removed from thelimiter 314. At least oneramp 328 is disposed upon an outer surface of thelimiter 314 over which therearward end 320 of thesleeve 312 slides when thesleeve 312 is moved to cover theforward tip 42 of theneedle cannula 36. Theramp 328 locks the sleeve in the extended position and prevents thesleeve 312 from being retracted toward theprefillable container 20 re-exposing theforward tip 42 once therearward end 320 of thesleeve 312 has been moved past theramp 328 in the direction of theforward tip 42. - Referring to
FIG. 9 , a further alternate embodiment of the needle assembly is generally shown at 410. Aneedle plunger 412 is inserted through thelimiter 414 at a generally perpendicular angle to theneedle cannula 36. Depressing apad 416 disposed on a distal end of theneedle plunger 412 drives theneedle plunger 412 inwardly of thelimiter 414. As shown inFIG. 10 ,needle plunger 412, when depressed, contacts and bends theneedle cannula 36 retracting theneedle cannula 36 into thelimiter 414 thereby shielding theforward tip 42 of thelimiter 414 to prevent exposure thereto. - As will now be understood, the
intradermal delivery device 10 of this invention includes a needle enclosure means, which encloses or conceals theneedle cannula tip 42 following injection and which preferably cannot be retracted to prevent accidental needle contact or reuse. In one embodiment shown inFIGS. 7 and 8 , the assembly includes anextendable shield 312, which locks in the extended position, preventing contact with theneedle cannula 36. In another embodiment shown inFIGS. 9 and 10 , theneedle cannula 36 is bent or deformed beyond its elastic limit byneedle plunger 412 to permanently enclose theforward tip 42 within thelimiter 414. - The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.
- Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, wherein reference numerals are merely for convenience and are not to be in any way limiting, the invention may be practiced otherwise than as specifically described.
Claims (35)
1. An intradermal needle assembly for use with a prefillable container having a reservoir capable of storing a substance for injection into the skin of an animal comprising:
a hub portion being attachable to the prefillable container;
a needle cannula supported by said hub portion and having a forward tip extending away from said hub portion; and
a limiter portion surrounding said needle cannula and including a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of said needle cannula and adapted to be received against the skin of the animal during administration of an intradermal injection, said limiter portion and said cannula being non-movable with respect to each other such that said needle forward tip extends beyond said skin engaging surface a distance ranging from approximately 0.5 mm to 3.0 mm wherein said limiter portion limits penetration of the needle into the dermis layer of skin of the animal so that the vaccine is injected into the dermis layer of the animal further including a sleeve circumscribing said limiter and being slidable for shielding said forward tip subsequent to administering an intradermal injection.
2. An assembly as set forth in claim 1 , wherein said limiter includes at least one ramp allowing said limiter to be moved toward said forward tip and preventing said limiter from being moved away from said forward tip upon shielding said forward tip.
3. An assembly as set forth in claim 2 , further including a tip cap removably affixed to said skin engaging surface and having said forward tip received therein.
4. An intradermal needle assembly for use with a prefillable container having a reservoir capable of storing a substance for injection into the skin of an animal comprising:
a hub portion having a throat for receiving the prefillable container;
a needle cannula being supported by said hub portion and having a forward tip extending away from said hub portion;
a limiter portion surrounding said hub portion and said needle cannula and including a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of said needle cannula and being adapted to be received against the skin of an animal, said limiter portion and said needle cannula being non-movable with respect to each other such that said forward tip extends beyond said skin engaging surface a distance ranging from approximately 0.5 mm to approximately 3.0 mm wherein the limiter portion limits penetration of said needle cannula into the dermis layer of the skin of the animal thereby injecting the substance into the dermis layer of the animal wherein said skin engaging surface comprises a rigid polymer having an elastomeric central area with said needle cannula extending therethrough.
5. An assembly as set forth in claim 4 , further including a sleeve circumscribing said limiter and being slidable for shielding said forward tip subsequent to administering an intradermal injection.
6. An assembly as set forth in claim 5 , wherein said limiter includes at least one ramp allowing said limiter to be moved toward said forward tip and preventing said limiter from being moved away from said forward tip upon shielding said forward tip.
7. An assembly as set forth in claim 6 , further including a tip cap removably affixed to said skin engaging surface and having said forward tip received therein.
8. An assembly as set forth in claim 4 , wherein said limiter includes a needle plunger slidably received thereby and being oriented generally perpendicular to said axis of said needle cannula.
9. An assembly as set forth in claim 8 , wherein said needle plunger is depressable thereby bending said needle cannula and retracting said needle cannula into said limiter for shielding said forward tip subsequent to administering an injection.
10. An intradermal needle assembly attachable to a prefillable container having a reservoir adapted to contain a substance for use in intradermally injecting vaccines into the skin of an animal, comprising:
a hub portion;
a needle cannula affixed to said hub portion and having a forward tip that is adapted to penetrate an the skin of an animal; and
a limiter surrounding said needle cannula and having a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of said needle cannula and being adapted to be placed against the skin of the animal during administration of an intradermal injection of the substance, said limiter and said needle cannula forward tip being non-movable with respect to each other such that said needle cannula forward tip extends away from said skin engaging surface a distance ranging from approximately 0.5 mm to approximately 3.0 mm and wherein said limiter limits penetration of said needle cannula forward tip into the dermis layer of the skin of an animal so that the substance is injected into the dermis layer of the skin further including a sleeve circumscribing said limiter and being slidable for shielding said forward tip subsequent to administering an intradermal injection.
11. An assembly as set forth in claim 10 , wherein said limiter includes at least one ramp allowing said limiter to be moved toward said forward tip and preventing said limiter from being moved away from said forward tip upon shielding said forward tip.
12. An assembly as set forth in claim 11 , further including a tip cap removably affixed to said skin engaging surface and having said forward tip received therein.
13. An assembly as set forth in claim 10 , wherein said limiter includes a needle plunger slidably received thereby and being oriented generally perpendicular to said axis of said needle cannula.
14. An assembly as set forth in claim 13 , wherein said needle plunger is depressable thereby bending said needle cannula and retracting said needle cannula into said limiter for shielding said forward tip subsequent to administering an injection.
15. An intradermal needle assembly for use with a prefillable container having a reservoir capable of storing a substance for injection into the skin of an animal comprising:
a hub portion attachable to the prefillable container;
a needle cannula supported by said hub portion and having a forward tip extending away from said hub portion;
a limiter portion surrounding said needle cannula and including a generally flat skin engaging surface extending in a plane generally perpendicular to an axis of said needle cannula and adapted to be received against the skin of the animal during administration of an intradermal injection, said needle forward tip extending beyond said skin engaging surface a distance ranging from approximately 0.5 mm to 3.0 mm wherein said limiter portion limits penetration of the needle into the dermis layer of skin of the animal so that the vaccine is injected into the dermis layer of the animal; and
an enclosure means for concealing said needle cannula following injection.
16. An assembly as set forth in claim 15 , wherein said enclosure means comprises said limiter being slideably disposed about said needle cannula and having at least a first position and a second position, said first position exposing said forward tip of said needle cannula and said second position concealing said forward tip of said needle cannula.
17. An assembly as set forth in claim 16 , wherein said limiter defines at least one slot oriented generally parallel to said needle cannula and having a protuberance disposed on one side thereof.
18. An assembly as set forth in claim 17 , further comprising a hub supporting said needle cannula and said hub including at least one locking finger and at least one stop, said at least one locking finger being cantilevered away from said forward tip and said at least one stop being cantilevered toward said forward tip.
19. An assembly as set forth in claim 18 , wherein said at least one locking finger includes a tab received by said slot disposed in said limiter.
20. An assembly as set forth in claim 19 , wherein said tab is snappable over said protuberance for moving said limiter from said first position to said second position.
21. An assembly as set forth in claim 20 wherein said needle plunger is depressable thereby bending said needle cannula and retracting said needle cannula into said limiter for shielding said forward tip subsequent to administering an injection.
22. An assembly as set forth in claim 21 , wherein said protuberance is disposed between said tab and said at least one stop when said limiter is located in said first position.
23. An assembly as set forth in claim 22 , wherein said limiter includes a catch engaging said at least one stop when said limiter is in said second position thereby preventing said limiter from being moved into said first position from said second position.
24. An assembly as set forth in claim 15 , wherein said limiter comprises a non-elastomeric polymer.
25. An assembly as set forth in claim 24 , wherein said skin engaging surface comprises an elastomeric polymer being circumscribed by said non-elastomeric polymer.
26. An assembly as set forth in claim 25 , wherein said elastomeric polymer is pierced by said needle cannula when said limiter is mated to said hub portion.
27. An assembly as set forth in claim 26 , wherein said forward end includes a beveled tip ranging in length between approximately 0.8 mm and 1.0 mm.
28. An assembly as set forth in claim 27 , wherein said forward end includes a beveled tip having a length of approximately 0.9 mm in length.
29. An assembly as set forth in claim 15 , wherein said enclosure means comprises a needle plunger inserted through said limiter and being depressable for bending said needle cannula thereby retracting said needle cannula into said limiter.
30. An assembly as set forth in claim 29 , wherein said needle plunger is oriented generally perpendicular to said needle cannula.
31. An assembly as set forth in claim 15 , including a cap attachable to said skin engaging surface for concealing said forward tip.
32. An assembly as set forth in claim 31 , wherein said cap comprises an elastomer and said forward tip is inserted into said elastomer thereby sealing said needle cannula and preventing said substance from leaking from said prefillable container through said cannula.
33. An assembly as set forth in claim 15 , wherein said enclosure means comprises a tubular shield extendable from a retracted position to an extended position enclosing said needle cannula.
34. An assembly as set forth in claim 15 , wherein said needle forward tip extends beyond said skin engaging surface about 1.0 to 2.0 mm.
35. An assembly as set forth in claim 16 , wherein said needle forward tip extends beyond said skin engaging surface 1.5 mm±0.2 to 0.3 mm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/554,280 US20090326452A1 (en) | 1999-10-14 | 2009-09-04 | Intradermal needle |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/417,671 US6494865B1 (en) | 1999-10-14 | 1999-10-14 | Intradermal delivery device including a needle assembly |
US09/834,438 US6843781B2 (en) | 1999-10-14 | 2001-04-13 | Intradermal needle |
US11/010,175 US20050113753A1 (en) | 1999-10-14 | 2004-12-10 | Intradermal needle |
US12/554,280 US20090326452A1 (en) | 1999-10-14 | 2009-09-04 | Intradermal needle |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/010,175 Division US20050113753A1 (en) | 1999-10-14 | 2004-12-10 | Intradermal needle |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090326452A1 true US20090326452A1 (en) | 2009-12-31 |
Family
ID=29219048
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/834,438 Expired - Lifetime US6843781B2 (en) | 1999-10-14 | 2001-04-13 | Intradermal needle |
US11/010,175 Abandoned US20050113753A1 (en) | 1999-10-14 | 2004-12-10 | Intradermal needle |
US12/554,280 Abandoned US20090326452A1 (en) | 1999-10-14 | 2009-09-04 | Intradermal needle |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/834,438 Expired - Lifetime US6843781B2 (en) | 1999-10-14 | 2001-04-13 | Intradermal needle |
US11/010,175 Abandoned US20050113753A1 (en) | 1999-10-14 | 2004-12-10 | Intradermal needle |
Country Status (1)
Country | Link |
---|---|
US (3) | US6843781B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8506476B1 (en) | 2011-10-25 | 2013-08-13 | James Wright O'Mara, Jr. | Injection device for endoscopy |
EP2554206A4 (en) * | 2010-03-30 | 2017-12-20 | Terumo Kabushiki Kaisha | Injection needle assembly and drug injection device |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7241275B2 (en) * | 1999-10-14 | 2007-07-10 | Becton, Dickinson And Company | Intradermal needle |
US6494865B1 (en) * | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
JP2004536785A (en) * | 2001-02-23 | 2004-12-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | New vaccine |
EP2269639B1 (en) * | 2001-02-23 | 2018-11-28 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
CA2445120A1 (en) * | 2001-04-27 | 2002-11-07 | Glaxosmithkline Biologicals Sa | Devices for the intradermal administration of influenza vaccines |
US20030073609A1 (en) * | 2001-06-29 | 2003-04-17 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
CA2460063C (en) * | 2001-09-12 | 2010-07-20 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
US20070005017A1 (en) * | 2002-02-04 | 2007-01-04 | Becton, Dickinson And Company | Intradermal delivery device with crenellated skin engaging surface geometry |
JP4613158B2 (en) | 2003-01-30 | 2011-01-12 | ベクトン・ディキンソン・アンド・カンパニー | Intradermal delivery device formed with skin engaging surface shape |
US8932264B2 (en) * | 2003-08-11 | 2015-01-13 | Becton, Dickinson And Company | Medication delivery pen assembly with needle locking safety shield |
MXPA06002047A (en) * | 2003-08-28 | 2006-05-25 | Becton Dickinson Co | Intradermal injection device. |
US7998119B2 (en) * | 2003-11-18 | 2011-08-16 | Nano Pass Technologies Ltd. | System and method for delivering fluid into flexible biological barrier |
US7108679B2 (en) * | 2004-03-11 | 2006-09-19 | Becton, Dickinson And Company | Intradermal syringe and needle assembly |
JP2008519042A (en) * | 2004-11-03 | 2008-06-05 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Influenza vaccination |
CA2587216C (en) * | 2004-11-18 | 2014-11-18 | Nanopass Technologies Ltd. | System and method for delivering fluid into flexible biological barrier |
US20070060904A1 (en) * | 2005-03-14 | 2007-03-15 | Becton, Dickinson And Company | Filling system and method for syringes with short needles |
CA2550114C (en) | 2005-06-20 | 2013-11-19 | Sherwood Services, Ag | Safety shield for medical needles |
WO2007047539A2 (en) * | 2005-10-14 | 2007-04-26 | Medtronic, Inc. | Localized delivery to the lymphatic system |
LT1965823T (en) * | 2005-11-04 | 2016-10-10 | Glaxosmithkline Llc | Methods for administering hypoglycemic agents |
US7842008B2 (en) * | 2005-11-21 | 2010-11-30 | Becton, Dickinson And Company | Intradermal delivery device |
US8492097B2 (en) * | 2006-04-24 | 2013-07-23 | Diagnostic Hybrids, Inc. | Compositions and methods for human metapneumovirus monoclonal antibodies |
US9358348B2 (en) * | 2006-06-14 | 2016-06-07 | Covidien Lp | Safety shield for medical needles |
US7811254B2 (en) * | 2006-10-18 | 2010-10-12 | Meridian Medical Technologies, Inc. | Autoinjector with needle depth adapter |
JP2010529166A (en) * | 2007-06-14 | 2010-08-26 | クルセル スウィツァーランド アーゲー | Intradermal influenza vaccine |
CA2695399C (en) * | 2007-08-02 | 2017-10-17 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
CA2639322C (en) * | 2007-09-07 | 2016-11-08 | Becton, Dickinson And Company | Pen needle hub having increased contact area |
US8827956B2 (en) | 2008-11-07 | 2014-09-09 | Becton, Dickinson And Company | Syringe housing to facilitate medication injection |
US8449504B2 (en) * | 2009-11-11 | 2013-05-28 | Calibra Medical, Inc. | Wearable infusion device and system |
WO2011067758A2 (en) | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
US9849247B2 (en) | 2010-02-01 | 2017-12-26 | Becton, Dickinson And Company | Low dose prefilled drug delivery device and method |
JP5781095B2 (en) * | 2010-02-05 | 2015-09-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Medicinal module with lockable needle guard |
WO2012023938A1 (en) | 2010-08-19 | 2012-02-23 | West Pharmaceutical Services, Inc. | Rigid needle shield |
CN103517713A (en) | 2011-02-22 | 2014-01-15 | 彼昂德瓦克斯医药有限公司 | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
EP2574359A1 (en) * | 2011-09-27 | 2013-04-03 | Sanofi-Aventis Deutschland GmbH | Needle safety device |
ES2702278T3 (en) | 2012-04-01 | 2019-02-28 | Technion Res & Dev Foundation | Extracellular matrix metalloproteinase (emmprin) inducer peptides and binding antibodies |
US10064990B2 (en) * | 2012-07-16 | 2018-09-04 | Becton, Dickinson And Company | Packageless syringe assembly with sterilizable fluid path |
US11577030B2 (en) | 2013-12-04 | 2023-02-14 | Embecta Corp. | Pen needle attachment mechanisms |
CA3148863A1 (en) | 2013-12-04 | 2015-06-11 | Becton, Dickinson And Company | Pen needle attachment mechanisms |
CA2944768C (en) | 2014-04-03 | 2022-08-30 | Biondvax Pharmaceuticals Ltd. | Compositions of multimeric-multiepitope influenza polypeptides and their production |
CN104338215B (en) * | 2014-11-04 | 2017-02-01 | 贝普医疗科技有限公司 | Disposable use safe self-destruction insulin needle |
GB2532795A (en) * | 2014-11-28 | 2016-06-01 | Owen Mumford Ltd | Retractable needle assemblies |
KR20170097020A (en) | 2014-12-23 | 2017-08-25 | 오토메드 피티와이 리미티드 | Delivery apparatus, system and associated methods |
CA2975046C (en) | 2015-01-30 | 2023-09-19 | Becton, Dickinson And Company | Pen needle hub with a patient contact surface |
US10828235B2 (en) | 2015-11-30 | 2020-11-10 | Becton, Dickinson And Company | Short injection length syringe |
JP2020501724A (en) * | 2016-12-16 | 2020-01-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Spacer for syringe |
IT201700059104A1 (en) * | 2017-05-30 | 2018-11-30 | Sol Millennium Swiss R&D Center Sa | SAFETY NEEDLE WITH CANNULA DEFORMATION FOR INJECTOR PEN |
WO2019204109A1 (en) * | 2018-04-19 | 2019-10-24 | Becton, Dickinson And Company | Pen needle container |
CN109718429B (en) * | 2019-02-15 | 2024-01-16 | 贝普医疗科技股份有限公司 | Safety insulin needle |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3890971A (en) * | 1973-10-23 | 1975-06-24 | Thomas A Leeson | Safety syringe |
US5019051A (en) * | 1989-03-02 | 1991-05-28 | Needlepoint Guard, Inc. | Hypodermic needle guard |
US5141496A (en) * | 1988-11-03 | 1992-08-25 | Tino Dalto | Spring impelled syringe guide with skin penetration depth adjustment |
US6494865B1 (en) * | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US6776776B2 (en) * | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE596981C (en) * | 1931-10-30 | 1934-05-12 | Mario Demarchi Dr | Injection syringe |
US2664086A (en) | 1950-08-15 | 1953-12-29 | Gerald O Transue | Automatic injector for hypodermic needles |
US2876770A (en) | 1955-10-10 | 1959-03-10 | Raymond A White | Shielded hypodermic syringe |
DE1166419B (en) | 1958-09-03 | 1964-03-26 | Dr Fritz Linder | Injection syringe |
US3400715A (en) | 1966-01-04 | 1968-09-10 | Halvard J. Pederson | Attachment for injection apparatus |
US4060073A (en) * | 1976-03-19 | 1977-11-29 | Medi-Ray, Inc. | Syringe shield |
DE2929425A1 (en) | 1979-07-20 | 1981-02-12 | Lothar Kling | DEVICE FOR INJECTION SYRINGES FOR INTRAMUSCULAR AND SUBENTANE INJECTION |
US4270537A (en) * | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
JPS5825171A (en) | 1981-08-06 | 1983-02-15 | テルモ株式会社 | Syringe |
CA1231016A (en) * | 1983-01-23 | 1988-01-05 | Amir Porat | Syringe |
US4619651A (en) * | 1984-04-16 | 1986-10-28 | Kopfer Rudolph J | Anti-aerosoling drug reconstitution device |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4774948A (en) * | 1986-11-24 | 1988-10-04 | Markham Charles W | Marking and retraction needle having retrievable stylet |
DE3642164A1 (en) * | 1986-12-10 | 1988-06-23 | Basf Ag | METHOD FOR REMOVING ACID FROM CATHODIC ELECTRO-DIP LACQUER BATHS BY ELECTRODIALYSIS |
US4886499A (en) * | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
GB8704027D0 (en) * | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4883473A (en) | 1987-04-29 | 1989-11-28 | Path | Single use injection device |
US4955871A (en) | 1987-04-29 | 1990-09-11 | Path | Single-use disposable syringe |
US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) * | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
GB2206794A (en) | 1987-07-14 | 1989-01-18 | Richard Kiteley Power | Syringe |
US4769003A (en) | 1987-08-19 | 1988-09-06 | Keith Stamler | Wound irrigation splashback shield |
US5195526A (en) * | 1988-03-11 | 1993-03-23 | Michelson Gary K | Spinal marker needle |
US5339163A (en) * | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US4834704A (en) * | 1988-04-13 | 1989-05-30 | Eaton Corporation | Injectable infusion pump apparatus for implanting long-term dispensing module and medication in an animal and method therefor |
US4978344A (en) | 1988-08-11 | 1990-12-18 | Dombrowski Mitchell P | Needle and catheter assembly |
US4898588A (en) | 1988-10-17 | 1990-02-06 | Roberts Christopher W | Hypodermic syringe splatter shield |
CA2016734C (en) * | 1989-06-02 | 1994-03-22 | Thomas J. Dragosits | Syringe assembly |
EP0423864A1 (en) * | 1989-10-16 | 1991-04-24 | Duphar International Research B.V | Training device for an automatic injector |
US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
GB8926825D0 (en) | 1989-11-28 | 1990-01-17 | Glaxo Group Ltd | Device |
US5697901A (en) * | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
US5437647A (en) * | 1990-05-09 | 1995-08-01 | Safety Syringes, Inc. | Disposable self-shielding aspirating syringe |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) * | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5331954A (en) * | 1990-12-21 | 1994-07-26 | Novo Nordisk A/S | Device for nasal delivery of liquid medications |
US5222949A (en) | 1991-07-23 | 1993-06-29 | Intermed, Inc. | Flexible, noncollapsible catheter tube with hard and soft regions |
DE4127887C1 (en) | 1991-08-22 | 1993-01-28 | Manfred Prof. Dr. 8520 Erlangen De Herbst | Subcutaneous medicine delivery device preventing needle from exceeding required depth - comprises tube attached with needle free to move on wedge shaped needle holder with needle penetration holes of different depth |
GB9118204D0 (en) * | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (en) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | INJECTION NEEDLE ARRANGEMENT |
NZ244980A (en) | 1991-11-15 | 1994-07-26 | Delta West Pty Ltd | Injection device operated by a deformable plastics ampoule |
IL101720A (en) | 1992-04-29 | 1998-09-24 | Mali Tech Ltd | Needle for syringe or the like |
US5431155A (en) * | 1992-06-03 | 1995-07-11 | Elettro Plastica S.P.A. | Single-dose nasal dispenser for atomized liquid drugs |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) * | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) * | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
US5569212A (en) * | 1994-07-22 | 1996-10-29 | Raya Systems, Inc. | Apparatus for electrically determining injection doses in syringes |
US5540664A (en) * | 1993-05-27 | 1996-07-30 | Washington Biotech Corporation | Reloadable automatic or manual emergency injection system |
WO1995001198A1 (en) | 1993-07-02 | 1995-01-12 | Ji Hoon Park | Syringe |
FR2715071B1 (en) * | 1994-01-17 | 1996-03-01 | Aguettant Lab | Automatic drug injector. |
US5514107A (en) * | 1994-02-10 | 1996-05-07 | Habley Medical Technology Corporation | Safety syringe adapter for cartridge-needle unit |
WO1995024176A1 (en) * | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) * | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5368578A (en) * | 1994-03-10 | 1994-11-29 | Sterling Winthrop Inc. | Hypodermic syringe holder |
US5519931A (en) * | 1994-03-16 | 1996-05-28 | Syncor International Corporation | Container and method for transporting a syringe containing radioactive material |
FR2718357B1 (en) * | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Improvements made to a needleless jet injection device. |
GB9412301D0 (en) * | 1994-06-17 | 1994-08-10 | Safe T Ltd | Hollow-needle drugs etc applicators |
US5496286A (en) * | 1994-08-17 | 1996-03-05 | Sterling Winthrop | Hypodermic syringe holder with disposable body |
US5582598A (en) * | 1994-09-19 | 1996-12-10 | Becton Dickinson And Company | Medication delivery pen with variable increment dose scale |
JP3208525B2 (en) * | 1995-01-05 | 2001-09-17 | 電気化学工業株式会社 | Sodium hyaluronate solution injection and container for injection |
US5599302A (en) * | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
CA2213682C (en) * | 1995-03-07 | 2009-10-06 | Eli Lilly And Company | Recyclable medication dispensing device |
US6090077A (en) * | 1995-05-11 | 2000-07-18 | Shaw; Thomas J. | Syringe plunger assembly and barrel |
DE19518810A1 (en) * | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal applicator |
SE9502285D0 (en) * | 1995-06-22 | 1995-06-22 | Pharmacia Ab | Improvements related to injections |
US5899879A (en) * | 1995-12-19 | 1999-05-04 | Genesis Medical Technologies, Inc. | Spring-actuated needleless injector |
US5893397A (en) * | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
US6090080A (en) * | 1996-07-05 | 2000-07-18 | Disetronic Licensing Ag | Injection device for injection of liquid |
US5993412A (en) * | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
DE19740187C1 (en) * | 1997-09-12 | 1999-04-15 | Disetronic Licensing Ag | Dosing unit, e.g. for medicines |
US5944700A (en) | 1997-09-26 | 1999-08-31 | Becton, Dickinson And Company | Adjustable injection length pen needle |
IE970782A1 (en) * | 1997-10-22 | 1999-05-05 | Elan Corp | An improved automatic syringe |
US6203529B1 (en) | 1997-11-19 | 2001-03-20 | B D Medico | Needle arrangement |
US6482176B1 (en) | 1997-11-27 | 2002-11-19 | Disetronic Licensing Ag | Method and device for controlling the introduction depth of an injection needle |
CA2315146C (en) | 1997-12-16 | 2008-11-18 | Meridian Medical Technologies, Inc. | Automatic injector for administrating a medicament |
IT1298087B1 (en) * | 1998-01-08 | 1999-12-20 | Fiderm S R L | DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS |
US6096010A (en) * | 1998-02-20 | 2000-08-01 | Becton, Dickinson And Company | Repeat-dose medication delivery pen |
US6090082A (en) * | 1998-02-23 | 2000-07-18 | Becton, Dickinson And Company | Vial retainer interface to a medication delivery pen |
JP4118399B2 (en) | 1998-07-21 | 2008-07-16 | テルモ株式会社 | Puncture adjusting tool for injection needle and injection needle assembly including the same |
US6112743A (en) * | 1998-09-04 | 2000-09-05 | Wolfe Tory Medical, Inc. | Connector for syringe and atomizer and the like |
TW373505U (en) * | 1999-01-28 | 1999-11-01 | Perfect Medical Industry Co Ltd | Improved structure for the safety syringe barrel |
US6036675A (en) * | 1999-02-03 | 2000-03-14 | Specialized Health Products, Inc. | Safety sterile cartride unit apparatus and methods |
WO2000056384A1 (en) | 1999-03-19 | 2000-09-28 | Peter Balfour Dugmore | An adjustable needle assembly |
US6379336B1 (en) | 1999-06-18 | 2002-04-30 | Hooman A. Asbaghi | Protective device for injection or aspiration needle |
US6368303B1 (en) * | 1999-10-15 | 2002-04-09 | Becton, Dickinson And Company | Retracting needle syringe |
DE29918794U1 (en) | 1999-10-26 | 1999-12-30 | Hoelzle Dieter Tech Projekte | Carpule for taking a medicine |
-
2001
- 2001-04-13 US US09/834,438 patent/US6843781B2/en not_active Expired - Lifetime
-
2004
- 2004-12-10 US US11/010,175 patent/US20050113753A1/en not_active Abandoned
-
2009
- 2009-09-04 US US12/554,280 patent/US20090326452A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3890971A (en) * | 1973-10-23 | 1975-06-24 | Thomas A Leeson | Safety syringe |
US5141496A (en) * | 1988-11-03 | 1992-08-25 | Tino Dalto | Spring impelled syringe guide with skin penetration depth adjustment |
US5019051A (en) * | 1989-03-02 | 1991-05-28 | Needlepoint Guard, Inc. | Hypodermic needle guard |
US6494865B1 (en) * | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US6776776B2 (en) * | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
US7083599B2 (en) * | 1999-10-14 | 2006-08-01 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
US7597684B2 (en) * | 1999-10-14 | 2009-10-06 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2554206A4 (en) * | 2010-03-30 | 2017-12-20 | Terumo Kabushiki Kaisha | Injection needle assembly and drug injection device |
US8506476B1 (en) | 2011-10-25 | 2013-08-13 | James Wright O'Mara, Jr. | Injection device for endoscopy |
Also Published As
Publication number | Publication date |
---|---|
US20050113753A1 (en) | 2005-05-26 |
US6843781B2 (en) | 2005-01-18 |
US20020068909A1 (en) | 2002-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6843781B2 (en) | Intradermal needle | |
US8066680B2 (en) | Prefillable intradermal delivery device | |
EP1379299B1 (en) | Prefillable intradermal injector | |
US6569123B2 (en) | Prefillable intradermal injector | |
CA2444372C (en) | Intradermal needle | |
AU2007203540B2 (en) | Prefillable intradermal delivery device | |
EP1858474B1 (en) | Filling system and method for syringes with short needles | |
CA2444377C (en) | Method of intradermally injecting substances | |
AU2001297971A1 (en) | Prefillable intradermal injector | |
US20020193778A1 (en) | Method of intradermally injecting substances | |
AU2001253514A1 (en) | Intradermal needle | |
ZA200307920B (en) | Intradermal needle. | |
JP4764593B2 (en) | Pre-fillable intradermal delivery device | |
AU2007205713A1 (en) | Intradermal needle | |
ZA200307923B (en) | Prefillable intradermal delivery device. | |
AU2001257048A1 (en) | Prefillable intradermal delivery device | |
ZA200307922B (en) | Prefillable intradermal injector. | |
ZA200307919B (en) | Method of intradermally injecting substances. | |
AU2007205712A1 (en) | Method of intradermally injecting substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BECTON, DICKINSON AND COMPANY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALCHAS, PAUL G.;LAURENT, PHILIPPE EMILE FERNAND;GUILLERMO, CARLOS E.;AND OTHERS;REEL/FRAME:023202/0261;SIGNING DATES FROM 20011022 TO 20011030 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |